[131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors.
Dosimetry and therapeutic application of [(131)I]-Tyr3-octreotide were evaluated in three patients with metastatic paraganglioma and carcinoid tumor. The in vitro stability of [(131)I]-Tyr3-octreotide was verified. Tumor uptake and residence time were between 0.02 and 0.1% and 0.5 to 9.8 h, respectively. The calculated tumor radiation doses were between 0.105 and 0.696 mGy.MBq(-1). No intolerance or adverse effects were observed after the therapeutic doses (3.3-6.6 GBq). A partial tumor response was obtained in one patient and no response occurred in two patients.
Baulieu
J
J
Department of Nuclear Medicine, Hôpital Bretonneau, Tours, France. baulieu@med.univ-tours
Resche
I
I
Bardies
M
M
Chauvet
A F
AF
Lecloirec
J
J
Malhaire
J
J
Thomas
E
E
Faurous
P
P
Sassolas
G
G
Pourcelot
L
L
Chatal
J
J
Guilloteau
D
D
Besnard
J C
JC
D000328:Adult; D002276:Carcinoid Tumor / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D007553:Isotope Labeling; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010235:Paraganglioma / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; C045210:3-Tyr-octreotide; D015282:Octreotide